Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 31 July 2012 | By Ansis Helmanis
Newly proposed safety-related revision from Canadian regulators will apply to acetylsalicylic acid (ASA)-containing products, and contains proposed limits for over-the-counter (OTC) use.
The product, more commonly referred to as aspirin, is increasingly found in combination products containing, for example, codeine and caffeine.
The draft proposal responds to adverse event reports concerning overdoses from products containing ASA, as well as risks to infant health posed by codeine use by nursing mothers. The draft guidance does not apply to products used by children under 12 years of age or for products used for cardiovascular protection or stroke prevention. The deadline for comments is 27 September 2012.
Read more:
Health Canada - Release of Draft Guidance Document: Acetylsalicylic Acid Labelling Standard
Get more Breaking News from RegLink
Tags: Draft Regulation, ASA, Aspirin